Korsana Biosciences, Inc.
KRSA
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.44M
Close$
$4.12
87.7% downside
Current Fair Value
87.7% downsideOvervalued by 87.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.44 Million |
|---|---|
| Enterprise Value | $19.04 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.63 |
| Beta | 1.72 |
| Outstanding Shares | 607,286 |
Return
| Return on Equity | -131.85% |
|---|---|
| Return on Assets | -96.78% |
| Return on Invested Capital | -133.24% |
Valuation & Multiples
| P/E Ratio | -2.82 |
|---|---|
| PEG | -0.64 |
| Price to Sales | 11.22 |
| Price to Book Ratio | 4.21 |
| Enterprise Value to Revenue | 10.02 |
| Enterprise Value to EBIT | -2.81 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-3.45
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.85
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cyclerion Therapeutics Inc
1 employees
CEO: Jonathan Violin Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules ...